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Abstract 
Background: The COUGAR-02 trial recently showed survival and quality of life benefits of Docetaxel 
and active symptom control (DXL+ASC) over active symptom control (ASC) alone in patients with 
refractory oesophagogastric adenocarcinoma.  
Aim: To conduct an economic evaluation conforming to NICE technology appraisal guidance to 
evaluate the cost-effectiveness of DXL+ASC vs. ASC from the perspective of the English NHS. 
Methods: Cost-utility analyses were conducted using trial data. Utility values were captured using the 
EQ-5D completed by patients at 3 and 6 weekly intervals while resource use was captured using nurse-
completed report forms and patient-reports. Incremental cost-effectiveness ratios (ICERs) were 
calculated and the main outcome was cost per incremental quality-adjusted life year (QALY). Non-
parametric bootstrapping was conducted to capture sampling uncertainty and to generate a cost-
effectiveness acceptability curve (CEAC). The analysis horizon was the trial period (median follow-
up=12 months) and no modelling or discounting of future costs and benefits was conducted. 
Results: Average costs were £9,352 and £6,218 for DXL+ASC and ASC, respectively and average QALYs 
0.302 and 0.186, respectively. This yielded an ICER of £27,180 for DXL+ASC. DXL+ASC had a 24% chance 
of being cost-effective at a £20,000 QALY threshold (lambda) and a mean net monetary benefit of -
£821; this rose to 59% and £332 when the threshold was raised to £30,000. If NICE end of life criteria 
are applied the probability of cost-effectiveness increases to 90% (at lambda = £50,000). Results were 
robust to sensitivity analyses.  
Conclusions: DXL+ASC is likely to be cost-effective if an end of life premium is applied. Further research 
should determine the impact of different utility measurement strategies and different chemotherapy 
delivery modes on estimates of cost-effectiveness.  
Key points:   
 The first economic evaluation of Docetaxel-based chemotherapy for second-line treatment in 
stomach cancer  
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 Docetaxel has only a 24% chance of being cost-effective when the ICER threshold is £20,000 
but this increases to 90% if end of life criteria are applied 
 Novel treatments may continue to struggle to overcome the value for money hurdle when 
providing only modest benefits in patients with poor prognosis.   
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Introduction  
Oesophago-gastric cancer is the fifth most common type of cancer in the UK and is associated with 
poor prognosis and survival.(1) The recent COUGAR-02 randomised, controlled, open-labelled trial 
(ISRCTN13366390) compared Docetaxel chemotherapy plus active symptom control (DXL+ASC) and 
active symptom control (ASC) only in patients with advanced adenocarcinoma of the oesophagus, 
oesophagogastric junction, or stomach in the UK.(2) Patients (aged 18 and over) were included in the 
trial if their cancer had progressed within 6 months of treatment with a platinum-fluoropyrimidine 
combination. They were randomised on a 1:1 basis and those in the DXL+ASC arm received a dose of 
75 mg/m² of Docetaxel by intravenous infusion every 3 weeks for up to six cycles. ASC included 
treatments for symptoms such as pain (e.g. Morphone Sulphate), nausea (e.g. Metoclopramide) and 
dyspepsia (e.g. Omeprazole) and included community and hospice care. The intention-to-treat 
analysis followed-up 168 randomised patients to a median of 12 months. Results indicated that 
median overall survival in the DXL+ASC group was 5.2 months (95% CI 4·1–5·9) versus 3.6 months (3·3–
4·4) in the ASC group (hazard ratio 0·67, 95% CI 0·49–0·92; p=0·01).  There were quality of life and 
symptom reduction benefits with DXL+ASC patients reporting less pain (p=0·0008), less nausea and 
vomiting (p=0·02), less constipation (p=0·02), and lower dysphagia (p=0·02) and abdominal pain 
(p=0·01) than the ASC group. 
The trial investigators concluded that Docetaxel could be recommended as an appropriate second-
line treatment for this population. The cost-effectiveness of Docetaxel for second-line treatments in 
non-small cell lung cancer (3), prostate cancer (4), and breast cancer (5) has been explored with mixed 
results. However, few studies (e.g.(6)) have evaluated the value for money of the treatment strategy 
in stomach or oesophageal cancers. The aim of the current analysis was to conduct a trial-based 
economic evaluation of DXL+ASC versus ASC for refractory oesophagogastric adenocarcinoma from 
the perspective of the NHS using the COUGAR-02 data.  
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Materials and Methods 
The analysis adopted National Institute for Health and Care Excellence (NICE) reference case 
methods.(7) As such, it employed a cost-utility approach with costs calculated from the perspective of 
Health and Personal Social Services and with the primary outcome being cost per incremental quality-
adjusted life year (QALY).  
Utility assessment 
Utility was based on the EQ-5D (three-level)(8) and UK scoring tariff.(9) Patients completed the EQ-5D 
at baseline, during clinic visits at weeks 3, 6, 9, 12, then every 6 weeks for up to 1 year and then every 
3 months until death. QALY calculations were based on an area under the curve (AUC) approach where 
an average utility value was calculated between each adjacent EQ-5D completions, multiplied by the 
length of time between completions and divided by 365.25. Death was assumed to yield a utility value 
of ‘0’. Thus, for those who died, the last QALY contribution was taken as the average between the 
individual’s last completed EQ-5D value and 0; this accounts for the likely deterioration in health 
leading up to death. As in the trial efficacy analysis, the primary economic analysis censored survival 
of alive patients to the date they were last known to be alive (i.e. survival was not modelled forward). 
An additional sensitivity analysis used Kaplan-Meier-based mean survival imputations to estimate the 
survival of those who were alive at study close and calculated QALYs and costs for the additional 
survival period.(10)  
Costs 
Health care usage data were collected on primary care (e.g. GP contacts, nurse visits), social care (e.g. 
social worker or home help visits) and secondary care (e.g. hospital visits and stays).  Primary and 
social care resource use was gathered using specially-developed questionnaires completed by patients 
at the same time as the EQ-5D. Two methods were used to capture secondary care resource use: i) 
micro-level data using inpatient and outpatient case-report forms completed by the nurses at every 
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contact and costing each stay and visit based on the assessments (e.g. specialist consultant 
assessments and scans) received (although staff time and procedures were costed using Reference 
costs); ii) less granular, macro-level costing based on bundled unit costs for stays and procedures. The 
base case analysis employed costing method i) with method ii) used as a sensitivity analysis. Resource 
and equipment use were costed using unit costs from the PSSRU report (11), NHS reference costs (12), 
the British National Formulary (13)  and the Electronic Market Information Tool (eMit).(14) Unit costs 
(with the exception of medication costs) are included in supplementary Tables 1 to 3.  
The costs for Docetaxel were calculated per cycle and volume received (assuming dose= 75mg/m2) 
based on patients body surface area (BSA) at baseline. The net price of Docetaxel infusion of 20 
mg/mL: 1-mL vial was £8.47 (£7.06 +20% VAT)(14) and all treatments were assumed to consist of an 
appropriate number of these volume vials with any mg/mL above the required level assumed to be 
wastage. In addition, a chemotherapy administration cost of £171 (HRG SB12Z in NHS Reference costs) 
was included for every cycle. BSA was calculated using the DuBois method(15) and was replaced by 
the national average (BSA=1.79)(16) when missing. The costs for radiotherapy included £700 (NHS 
Reference cost HRG SC46Z) for initial treatment set-up and £108 per fraction received (NHS Reference 
cost HRG SC22Z). If the number of fractions was missing then the mean for the sample was used. All 
costs (excepting Docetaxel as the list price was from June 2013) were inflated to 2014 prices using an 
accepted cost converter based on Purchasing Power Parities.(17) 
Analysis 
If costs and effects were higher or costs and effects lower for one treatment strategy over another 
then incremental cost-effectiveness ratios (ICER) were calculated.(18) The ICER is calculated: 
(CostDXL+ASC-CostASC)/(QALYDXL+ASC–QALYASC) and yields the cost of obtaining an additional QALY for 
DXL+ASC. Interventions yielding ICERs above NICE’s willingness to pay threshold range of £20,000-
£30,000 per incremental QALY are not considered cost-effective and deemed an inefficient use of 
scarce resources. However, exceptions to the case may be made if a treatment extends life and meets 
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the NICE ‘end of life’ criteria.(7) Analyses explored the scenario where the end of life weighting is 
applied and the QALY gain (or threshold) is multiplied by 2.5. 
Non-parametric bootstrapping (n=10,000 simulations with replacement) was employed to determine 
the level of sampling uncertainty around the estimates of cost-effectiveness. The resulting 10,000 
incremental costs and effects are plotted on a cost-effectiveness plane. The ICER decision rule can be 
reformulated to generate incremental net monetary benefit (INMB) in the following manner: INMB = 
λ*(QALYDXL+ASC – QALYASC) - (CostDXL+ASC- CostASC) where λ = NICE threshold value. If INMB is positive 
given a particular λ then DXL+ASC is considered cost-effective. The bootstrapped NMB values were 
used to identify the probability that DXL+ASC was cost-effective given a range of λ, presented on a 
cost-effectiveness acceptability curve (CEAC) (19) and to determine non-parametric confidence 
intervals.(20) The net benefit regression framework was applied to permit parametric analysis of cost-
effectiveness controlling for heterogeneity.(21)  
Multiple imputation (m=20) based on a combination of predictive mean matching (pmm), logit and 
Poisson models, depending on the variable type, was used to handle missing data.(22) Hospital visits, 
medication, radiotherapy and Docetaxel costs were not imputed. Ambulance use, assessments and 
length of stay for hospital visits were imputed using treatment, demographic and clinical variables 
(e.g. cancer site, tumour type, previous surgery). EQ-5D utilities were imputed using the same 
variables when all items were missing and using additional information from completed items when 
only some were missing. Community care total costs were imputed using the same variables and 
average community care costs from completed patient-forms and patient secondary care costs. The 
means of the imputed values were used in the final analyses. 
A number of sensitivity analyses were conducted to test the sensitivity of the cost-effectiveness 
estimates to the methods adopted. Specifically, we tested the impact of: adopting different secondary 
care costing approaches (micro vs. macro); assuming fewer outpatient visits for chemotherapy; 
extrapolating QALYs forward for survivors; 10-20% changes in costs and QALYs to account for errors 
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in cost and benefit calculation; and adjusting for baseline EQ-5D. Discounting was not considered 
necessary as, except for a few instances, all costs and effects were observed within 12 months. All 
analyses were conducted in STATA 13© (StataCorp LP, Texas) and Excel© (Microsoft, Texas). 
Results 
Data were available from all 168 patients (84 patients in each arm). At the time of the analysis for the 
paper, 161 of the 168 (96%) patients had died, leaving only 7 patients alive and therefore with 
censored data. Of the 1171 expected patient resource use forms after accounting for survival, 527 
(45%) were completed. Multiple imputation was used to estimate the costs from the missing resource 
use forms. However, the primary care use reported therein represented a small proportion of overall 
costs and therefore imputation made little impact on the results. For example, community care mean 
(SD) costs per time-point for observed and imputed cases for the combined sample were £127.95 
(£360.42) and £119.60 (£147.71), respectively. Information on medication use and number of 
inpatient and outpatient stays was assumed complete as these were based on case-report forms 
completed by nurses. However, there was some missing data within those forms (for example for 117 
(50%) of 233 inpatient stays, details about ambulance use was missing) and this was also imputed. In 
general, missing data were minimal with less than 4% of stay length, ward type and EQ-5D scores 
missing.   
DXL+ASC patients received a median of three chemotherapy cycles (interquartile range 1-5) and had 
a median course dose intensity of 46% (interquartile range 19-76%). We didn’t specifically ask for G-
CSF usage but this may have come out in the medications used. During the course of trial follow-up, 
DXL+ASC patients stayed in hospital for an average of 14.45 (SD = 20.25; range 0-125) days compared 
to 7.68 (SD = 9.74; range 0-34) in the ASC arm (Supplementary Table 3); had 11.07 (SD = 9.36; range 
0-44) outpatient visits compared to 5.62 (SD = 5.38; range 0-19) in the ASC arm (Supplementary Table 
4); visited A&E on 0.13 occasions (SD = 0.43; range 0-3) compared to 0.01 (SD = 0.11; range 0-1) in the 
ASC arm; and visited the GP on 1.12 occasions (SD = 2.14; range = 0-9) compared to 0.87 occasions 
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(SD = 1.17; range 0-5) in the ASC arm (Supplementary Table 5). Thus resource use was higher in the 
DXL+ASC arm than the ASC arm in most areas. There were over 2,300 prescriptions of medication 
during the study of which the most common were for relief of pain (23%), nausea (12%), constipation 
(7%) and gastric symptoms such as dyspepsia (6%).  
The costs of the resource use (after imputation) are included in Table 1. Patients incurred both higher 
primary and secondary care costs in the DXL+ASC group. Medication costs (excluding Docetaxel itself) 
were higher in the DXL+ASC group than ASC group (£192 vs. £96). Of the prescription costs, 23% were 
<£1; 75% were <£5 and 99% were <£100. Mean medication costs of preventing and treating 
neutropenia and related sepsis was £8.89 (SD=£25.01) and £0.00 for the DXL+ASC and ASC arms, 
respectively.  Costs of medication for preventing and treating nausea and vomiting was £31.95 (SD= 
53.28) and £14.58 (SD=£37.17) for DXL+ASC and ASC arms, respectively.  Docetaxel chemotherapy 
costs were £798 on average and ranged £236-£1,770 while radiotherapy costs were substantively 
higher in the ASC group (£275 vs. £15 for DXL+ASC group). Inpatient costs were £1,632 higher in the 
DXL+ASC than the ASC group and this appeared to be driven by bed day costs. Outpatient costs were 
on average £674 greater in the DXL+ASC group which were driven by the higher number of visits and 
investigation costs. In total, DXL+ASC was found to be £3,134 (£9,352 vs. £6,218) more expensive than 
ASC alone.  
Baseline utility values were similar across arms (DXL+ASC = 0.69; ASC =0.70). However, an analysis 
adjusting for this difference was conducted as a sensitivity analysis.(23) Figure 1 shows the quality-
adjusted survival based on EQ-5D scores up to week 60. It shows a greater AUC for DXL+ASC compared 
to ASC with the former group experiencing average QALYs of 0.302 compared to 0.186 in the ASC 
group, an incremental QALY gain of 0.116. (See Supplementary Table 6 for utility values). 
Table 2 includes average patient costs and QALYs per trial arm and ICERs for the base case and 
sensitivity analyses. The results for the base case analysis indicate that DXL+ASC confers higher QALYs 
than ASC and is more costly. The mean bootstrapped ICER of £27,123 is above what is usually 
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considered cost-effective although well below a threshold of £50,000 following the application of the 
NICE end of life criteria. The results are robust to a number of sensitivity analyses where alternative 
costing and QALY calculation methods are employed and when cost and QALY estimates are varied by 
20% (Table 2). Reductions in costs and increases in QALYs (in both arms) by 20% leads to ICERs 
approaching £20,000. It is worth noting that the Macro-costing approach has the effect of reducing 
estimated costs in both arms but the overall effect on the ICER is minimal. Extrapolating the survival 
forward for individuals alive at trial end has minimal impact on QALYs gained and the ICER, partly due 
to the small number surviving the trial and because some of those are in health states worse than 
dead (i.e. their EQ-5D value is negative). Adjusting for baseline EQ-5D also had minimal impact on the 
ICER. Figure 2 illustrates that most of the simulated ICERs are in the north-east quadrant of the cost-
effectiveness plane with approximately a third falling below the (£20,000) cost-effectiveness 
threshold. The CEAC is presented in Figure 3 and shows that, where λ=£20,000 and λ=£30,000, 
DXL+ASC has a 24% and 59% chance, respectively, of being cost-effective. Ceteris paribus, the cost 
differential would have to be £2,306 or less or the QALY differential 0.16 or more for the ICER to fall 
under £20,000.  
The INMB means at thresholds of £20,000, £30,000 and £50,000 were -£821, £332 and £2,638, 
respectively (Table 2). For the same thresholds, net benefit regression indicated that - both with and 
without demographic and clinical covariates - the treatment arm was not a significant predictor of net 
benefit (see supplementary Table 7). In general, the models and coefficients were not significant but 
there was a trend (at λ=£30,000) for those who had received previous surgery deriving greater net-
benefit (incremental £3664; CI -£ 277 to £ 7607; p = 0.068) than those who had not. Interactions with 
the treatment variable also indicated there may be a differential treatment effect according to gender 
and tumour type (metastatic vs. locally advanced). 
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Table 1: Costs  
  DXL+ASC ASC 
    N Mean SD Min Max N Mean SD Min Max 
Patient-reported 
costs 
Primary care  84 £877 £1,503 £0 £11,511 84 £725 £789 £0 £5,214 
  Secondary care * 84 £94 £214 £0 £1,153 84 £51 £144 £0 £845 
Treatment costs Medication  84 £192 £268 £0 £1,342 84 £96 £118 £0 £541 
  Docetaxel  84 £798 £456 £236 £1,770 84 £0 £0 £0 £0 
  Radiotherapy  84 £15 £138 £0 £1,268 84 £275 £660 £0 £3,641 
Inpatient costs Ambulance 84 £142 £207 £0 £1,043 84 £48 £115 £0 £690 
  Stay  84 £2,912 £4,074 £0 £25,000 84 £1,553 £1,956 £0 £6,800 
  Clinical investigation  84 £556 £772 £0 £3,261 84 £311 £605 £0 £3,968 
  Diagnostic tests 84 £129 £179 £0 £890 84 £65 £102 £0 £556 
  Therapy  84 £320 £1,001 £0 £7,864 84 £848 £2,814 £0 £15,444 
  Lab tests 84 £646 £821 £0 £4,225 84 £315 £546 £0 £2,703 
  Other assessments 84 £2 £6 £0 £48 84 £1 £7 £0 £60 
  Other surgery 84 £67 £156 £0 £699 84 £67 £179 £0 £932 
Outpatient costs Ambulance 84 £60 £293 £0 £2,530 84 £25 £156 £0 £1,380 
  Stay  84 £930 £786 £0 £3,696 84 £472 £452 £0 £1,596 
  Clinical investigation  84 £1,000 £823 £0 £3,918 84 £615 £625 £0 £2,586 
  Diagnostic tests 84 £172 £191 £0 £771 84 £70 £207 £0 £1,653 
  Therapy  84 £88 £304 £0 £2,678 84 £447 £3,377 £0 £30,888 
  Laboratory tests 84 £52 £57 £0 £374 84 £27 £31 £0 £150 
  Other assessments 84 £0 £2 £0 £12 84 £0 £1 £0 £8 
Patient-reported costs 84 £971 £1,523 £0 £11,511 84 £776 £816 £0 £5,214 
Treatment costs 84 £1,004 £609 £236 £2,878 84 £371 £702 £0 £3,686 
Inpatient costs 84 £4,976 £5,642 £0 £26,823 84 £3,344 £4,648 £0 £23,140 
Outpatient costs 84 £2,401 £2,010 £0 £8,925 84 £1,727 £3,877 £0 £34,362 
Total costs 84 £9,352 £7,339 £384 £42,757 84 £6,218 £6,184 £252 £37,205 
*Excludes secondary care costs covered by nurse-completed case-report forms;  
DXL+ASC = Docetaxel and Active Symptom Control; ASC = Active Symptom Control; SD = Standard Deviation; Min = Minimum; Max = Maximum
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Table 2: Cost-effectiveness results 
Analysis Costs QALYs  
DXL+ASC ASC DXL+A
SC 
ASC ICER 
Base case      
Mean £9,352 £6,218 0.302 0.186 £27,180 
Lower CI £7,783 £4,895 
 
0.235 0.369  
Upper CI £10,922 £7,540 0.142 0.231  
Bootstrap simulated ICER      
Mean £9,355 £6,227 0.302 0.186 £27,123 
Deterministic Sensitivity Analyses      
Macro-costing approach* £8,148 £4,814 0.302 0.186 £28,915 
Fewer outpatient visits assumed** £8,416 £5,420 0.302 0.186 £25,986 
QALYs extrapolated for those still 
alive 
£9,355 £6,227 0.301 0.194 £29,086 
Adjusting for baseline differences in 
EQ-5D 
£9,352 £6,218 
0.302 0.186 
£27,030 
 
 
10% reduction in costs in DXL arm  £8,417 £6,218 0.302 0.186 £18,931 
20% reduction in costs in both arms £7,484 £4,982 0.302 0.186 £21,698 
20% increase in costs in both arms £11,226 £7,473 0.302 0.186 £32,547 
20% reduction in QALYs in both 
arms 
£9,355 £6,227 0.241 0.149 £33,903 
20% increase in QALYs in both arms £9,355 £6,227 0.362 0.223 £22,602 
 
Bootstrap simulated Net Monetary 
Benefit† (unadjusted) 
 
Willingness to pay Threshold (λ) 
 
λ = £20,000 
λ = 
£30,000 
λ = 
£50,000 
Mean (Lower CI, Upper CI) -£821 (-£3,097, 
£1,457) 
£332 (£1,457, 
£3,119) 
£2,638 (-£1,313, 
£6,753) 
DXL+ASC = Docetaxel and Active Symptom Control; ASC = Active Symptom Control; ICER=Incremental Cost-
Effectiveness Ratio; QALY = Quality-Adjusted Life Year; CI; Confidence Intervals; λ = Lambda/Willingness to pay 
threshold 
*Assumes one (higher) cost per (in-patient and out-patient) visit and excludes diagnostics, tests, 
assessments and other surgery; for DXL assumes outpatient cost includes chemotherapy administration 
**Removes outpatient visits at 3, 9 and 15 weeks  
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† Confidence Intervals based on 2.5th and 97.5th percentiles 
 
 
 
Discussion 
This economic evaluation conducted alongside the COUGAR-02 randomised clinical trial found that a 
strategy of Docetaxel plus active symptom control (DXL+ASC) versus active symptom control alone 
was more costly but was associated with greater benefits for refractory oesophagogastric 
adenocarcinoma. The cost per incremental QALY was, at around £27,000, above that normally 
considered cost-effective. Exploring the sampling uncertainty around the estimate revealed that 
chemotherapy had a 24% chance of being cost-effective. However, at a willingness to pay threshold 
of £30,000, there was a 59% chance of chemotherapy being cost-effective and a mean incremental 
net monetary benefit of £332. The ICERs remained in the range of £20,000-£30,000 after a series of 
deterministic sensitivity analyses providing some confidence in the robustness of the results. The cost 
differential was £3,134 and would need to fall by £828 for the ICER to drop below £20,000; this is 
roughly equivalent to two nights in hospital plus two outpatient visits. The incremental benefit of 
0.116 QALYs is roughly equivalent to 42 days of life with full health or 61 days additional life with the 
baseline level of quality of life. Using this latter level of quality of life, the additional life extension 
delivered by chemotherapy would have to be 82 days (assuming constant utility) for the ICER to fall 
below £20,000. Few studies have conducted cost-utility analyses of Docetaxel as a second-line 
therapy. Inter-study comparisons are difficult since existing evaluations are in none gastric cancers 
(e.g. (3-5)) or present non-UK data only.(6) Within these studies, findings were mixed as to whether 
Docetaxel was cost-effective (3) or not (5, 6) with ICERs ranging between £23,000-£33,000. However, 
the ICERs are clearly context-dependent and determined by the definition of standard care and 
comparators.  
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It is possible that the treatment strategy would be eligible for the End of Life (EoL) criteria set out by 
the NICE.(7) The EoL criteria have been challenged on ethical (24) and efficiency grounds (25), and 
may not reflect the preferences of society (26) but are still worthy of consideration. The NICE Appraisal 
Committee may accept analyses with additional QALY-weightings where i) the life expectancy of the 
group is less than 24 months; ii) there is evidence life is extended by a minimum of three months; iii) 
and the population in England eligible for treatment is less than 7,000.  Patients in this group would 
certainly meet the criteria of life expectancy of less than 24 months. A recent audit revealed that 9,768 
patients with oesophago-gastric cancer were treated with palliative treatment intent in England in 
2011-12 (1); as only a proportion would be receiving second-line chemotherapy, the annual eligible 
population would be less than 7,000. While the NICE EoL criteria i) and iii) are met, satisfaction of ii) is 
less clear as additional median life extension was 1.6 months (5.2 vs. 3.6 months) [mean = 1.8 months 
(6.6 vs. 4.8)] in the statistical evaluation; however it is likely that appraisal committees may have some 
flexibility in this regard. Should the criteria apply here and the willingness to pay threshold be 
increased to £40,000 or £50,000 per QALY (effectively a QALY-weighting of 2 and 2.5, respectively) 
then the probability that the DXL+ASC strategy would be cost-effective is 81% (mean INMB = £1,485) 
or 90% (mean INMB = £2,638).  
The data presented here are arguably more complete than that normally available to NICE Evidence 
Review Groups, and demonstrate that, even for an inexpensive treatment, it may be difficult to 
achieve cost-effectiveness. A possible conclusion is that, in order to achieve an ICER<£20,000, new 
treatments (which are generally more expensive) would need to show very much higher levels of 
effectiveness or lower resource use. The cost used here for Docetaxel is the genericized price and 
unlikely to decrease significantly in the future. Ramucirumab provides similar survival gains but costs 
>£7,000 per cycle (total > £28,000) compared to around £50 per cycle for Docetaxel (total 
approximately £150). Consequently, Ramucirumab would need to provide ceteris paribus more than 
an additional year of life (at full health) to achieve cost-effectiveness. This is almost certainly not 
achievable in a disease with a current median survival of <6 months and, hence, novel treatments are 
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unlikely to become available to UK patients at this price level. The NHS, industry and society need to 
consider the implications of this and agree a way forward which will provide affordable access to 
innovative medicines. 
Limitations  
The analyses were somewhat reliant (for the costs, at least) on multiple imputation which may have 
introduced additional uncertainty that was not fully captured or was underestimated in the analysis. 
However, data on survival, utility and secondary care costs were relatively complete. Furthermore, 
since  imputation had the largest role in dealing with missing community care costs which were a small 
proportion of overall costs, it is unlikely that it would have influenced results substantively. We 
assumed that nurse-completed case reports were accurate in that inpatient and outpatient visits were 
captured fully, but this may not have been the case and resource use may consequently have been 
underestimated. While the exploration of +/- 20% costs in both arms allows confidence that the 
decision would not change, this assumes that missing data and recording errors were equalised across 
arms. Any errors in accounting such as double counting may be greater for the DXL+ASC arm as there 
was more resource use therein. This evaluation used data from a single trial only. If there is sufficient 
decision uncertainty remaining in this clinical area, a model-based evaluation may be worthwhile as 
this would allow synthesis of effectiveness data from COUGAR-II and other Docetaxel trials (e.g.(27)) 
and permit comparisons with alternative therapies such as Ramucirumab (e.g.(28)). 
Finally, the analysis took the perspective of the NHS and omitted costs to the patient and their carers. 
If a wider perspective had been adopted it is likely that the results would have been less favourable 
for DXL+ASC since the private costs of travelling to hospital would have been higher in the DXL+ASC 
arm.  
Future research 
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Although the EQ-5D has been validated in cancer patients (29) there is evidence that it lacks sensitivity 
in this group (30), omits key constructs of importance and overstates the benefits of 
chemotherapy.(31) Recent efforts have sought to develop preference-based measures that capture 
issues such as nausea, constipation and other cancer-related issues.(32) Future analyses should 
explore the impact of (disease-specific) measure choice on estimates of cost-effectiveness. We found 
that there were non-trivial differences (£1,204) in costs according to the methods used, with macro-
costing yielding a figure 13% lower than micro-costing. This difference did not change the decision 
here but macro-level costing is common in economic studies and this approach may underestimate 
healthcare costs. Future analyses should be mindful of the impact of costing methods and where 
possible consider collecting micro-level data.  
 Assuming the QALY benefits observed here (after accounting for side-effects) are accurate and reflect 
true additional patient benefit, an obvious approach to enhancing the value of the chemotherapy 
strategy examined here would be to reduce delivery costs. The study protocol included visits every 
three weeks until week 18 which may be above that which would be expected in routine practice. 
Removing these and assuming visits every 6 weeks reduced the ICER to £25,986. Alternative 
approaches such as home delivery of IV chemotherapy may be a fruitful avenue for research. Such an 
intervention may bring additional quality of life benefits as it is known that those who are treated at 
the end of life would prefer to receive treatment at home (33) and it would also reduce resource 
costs.(34)  
Conclusions:  
The Docetaxel strategy had survival and quality-of-life benefits over active symptom control alone but 
was more costly. It was not deemed to be cost-effective unless additional ‘end-of-life’ QALY premiums 
were applied. The additional costs of chemotherapy delivery and patient resource use were important 
drivers of cost-effectiveness and future research should explore ways in which to reduce these. The 
analyses highlight important, more general, issues: that novel treatments may continue to struggle to 
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overcome the value for money hurdle when providing only modest benefits in patients with poor 
prognosis; that reliance on patient-reports for resource use in populations with severe disease may 
result in high levels of missing data; and that the methods of costing (micro vs. macro) may impact 
results.  
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